Recruiting

Testing a cholesterol drug to prevent nerve damage from myeloma treatment

Plain-English translation of NCT07025005 on ClinicalTrials.gov ↗ · Source last updated November 2025 · Translation generated June 2026 · How we translate trials

Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.

What is this trial?

Multiple myeloma is a serious blood cancer that requires strong chemotherapy to treat. One common chemotherapy combination (called VRd) works well but can cause painful nerve damage as a side effect. This trial is testing whether fenofibrate, a medication already used safely to manage cholesterol, might protect your nerves from this damage when taken alongside your myeloma treatment.

Nerve damage from this chemotherapy is a major problem that can cause lasting pain and disability, and there are currently no proven ways to prevent it. Early research suggests this medication might help by reducing inflammation in the nerves, so this trial is testing whether it actually works in patients like you.

Do you qualify?

You likely qualify if…

you are 18 years or older
you have been newly diagnosed with multiple myeloma
you are about to start or have just started the VRd chemotherapy regimen
you have adequate liver and kidney function based on blood tests
you have healthy blood cell counts (adequate neutrophils, platelets, and hemoglobin)

You likely don't qualify if…

you have had other chemotherapy drugs known to damage nerves in the past 6 months
you already have nerve damage from diabetes, autoimmune disease, or other causes
you are currently taking pain medications for neuropathy, certain antidepressants, or antioxidant vitamin supplements
you have liver disease, gallbladder disease, kidney disease, or serious inflammation in your digestive system
you are allergic to fenofibrate or taking medications that strongly interact with it, such as statins or blood thinners

What participation looks like

You will receive 6 cycles of your myeloma chemotherapy (standard treatment). If you're randomly assigned to the treatment group, you will also take a fenofibrate tablet (160 mg) by mouth once daily throughout all 6 cycles. Each cycle lasts 28 days. The study team will monitor you regularly with blood tests and check-ins to watch for side effects and see whether you develop nerve damage.

AI-generated summary from trial data · Jun 4, 2026 · Not medical advice

Testing a cholesterol drug to prevent nerve damage from myeloma treatment

What is this trial?

Do you qualify?

What participation looks like

Trial locations(2 sites)